Tianjin Pharmaceutical Da Ren Tang Group Estimates Increased Attributable Profit in H1

MT Newswires

2025/07/14

Tianjin Pharmaceutical Da Ren Tang (SGX:T14) estimated a net profit attributable to equity holders for the first six months of the year to range between 1.84 billion yuan to 2.0 billion yuan, according to a filing with the Singapore Exchange on Monday.

The increase will represent a 180% to 204% year over year.

The company has attributed this to the disposal of its remaining stake in Tianjin TSKF Pharmaceutical to Haleon China and Haleon CH SARL for around 1.54 billion yuan.

Shares of the company were up nearly 1% in recent trading.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2551010329"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2551010329\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2551010329?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-14 17:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2551010329","market":"sg","top_or_hot":-1,"title":"Tianjin Pharmaceutical Da Ren Tang Group Estimates Increased Attributable Profit in H1","media":"MT Newswires","content":"<html><body><p> Tianjin Pharmaceutical Da Ren Tang (<a href=\"https://laohu8.com/S/S68.SI\">SGX</a>:T14) estimated a net profit attributable to equity holders for the first six months of the year to range between 1.84 billion yuan to 2.0 billion yuan, according to a filing with the Singapore Exchange on Monday.</p><p>The increase will represent a 180% to 204% year over year.</p><p>The company has attributed this to the disposal of its remaining stake in Tianjin TSKF Pharmaceutical to <a href=\"https://laohu8.com/S/HLN\">Haleon</a> China and Haleon CH SARL for around 1.54 billion yuan.</p><p>Shares of the company were up nearly 1% in recent trading.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tianjin Pharmaceutical Da Ren Tang Group Estimates Increased Attributable Profit in H1</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTianjin Pharmaceutical Da Ren Tang Group Estimates Increased Attributable Profit in H1\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1060499803\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires </p>\n<p class=\"h-time\">2025-07-14 17:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Tianjin Pharmaceutical Da Ren Tang (<a href=\"https://laohu8.com/S/S68.SI\">SGX</a>:T14) estimated a net profit attributable to equity holders for the first six months of the year to range between 1.84 billion yuan to 2.0 billion yuan, according to a filing with the Singapore Exchange on Monday.</p><p>The increase will represent a 180% to 204% year over year.</p><p>The company has attributed this to the disposal of its remaining stake in Tianjin TSKF Pharmaceutical to <a href=\"https://laohu8.com/S/HLN\">Haleon</a> China and Haleon CH SARL for around 1.54 billion yuan.</p><p>Shares of the company were up nearly 1% in recent trading.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK6079","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2551010329","we_media_id":"1060499803","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2551010329","pubTimestamp":1752485759,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"MT Newswires","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1060499803","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Tianjin Pharmaceutical Da Ren Tang  estimated a net profit attributable to equity holders for the first six months of the year to range between 1.84 billion yuan to 2.0 billion yuan, according to a filing with the Singapore Exchange on Monday.The increase will represent a 180% to 204% year over year.The company has attributed this to the disposal of its remaining stake in Tianjin TSKF Pharmaceutical to Haleon China and Haleon CH SARL for around 1.54 billion yuan.Shares of the company were up nearly 1% in recent trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK6079":"制药","BK6506":"制药与医学研究概念","T14.SI":"达仁堂"},"translate_title":"天津制药大仁堂集团预计上半年归属利润增加","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"T14.SI":0.9},"content_text":"Tianjin Pharmaceutical Da Ren Tang (SGX:T14) estimated a net profit attributable to equity holders for the first six months of the year to range between 1.84 billion yuan to 2.0 billion yuan, according to a filing with the Singapore Exchange on Monday.The increase will represent a 180% to 204% year over year.The company has attributed this to the disposal of its remaining stake in Tianjin TSKF Pharmaceutical to Haleon China and Haleon CH SARL for around 1.54 billion yuan.Shares of the company were up nearly 1% in recent trading.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}